Adult Acute Lymphocytic Leukemia: Strategies for Selection of Consolidation Therapy
Consolidation therapy is a critical component of ALL therapy, with the goal of eliminating any leukemic cells potentially remaining after induction therapy, further eradicating residual disease. MRD assessment is an essential component of the evaluation of response to therapy in ALL.
Category
  • Acute Lymphoblastic Leukemia
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Case Studies in the Management of Leukemia
As a result of the therapeutic advances and clinical research affecting the management of patients with leukemia, clinicians can benefit by comparing their individual skills of diagnosis, treatment, and management of patients with their peers. This peer interaction is an integral part in enhancing clinical decision-making skills that can improve patient care.
Category
  • Acute Lymphoblastic Leukemia
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Recorded Presentation from the NCCN Pharmacy Updates: Updates in the Treatment of Adult Acute Lymphoblastic Leukemia
Side effects of novel therapies may be severe. Cytokine release syndrome, neurotoxicity, and sinusoidal obstruction syndrome (SOS/VOD) are just some of the serious adverse effects that may occur. With the expanding roles of monoclonal antibodies and CAR-T therapies in acute lymphoblastic leukemia (ALL), pharmacists should be aware of their proper place in therapy and side effect management for patient safety.
Category
  • Acute Lymphoblastic Leukemia
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation